Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Pharmaceutical Sciences

• Publication date

  2014-06-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejps.2014.01.012PMID 24561703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development

  2012cited by this paper
• Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors.

  2012influential reference
• Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients

  2012cited by this paper
• Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

  2011influential reference
• Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE).

  2011cited by this paper
• Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril.

  2010influential reference
• NONMEM User’s Guides. (1989–2009)

  2009influential reference
• Angiotensin-Converting Enzyme C-Terminal Catalytic Domain Is the Main Site of Angiotensin I Cleavage In Vivo

  2008influential reference
• Mechanism-based concepts of size and maturity in pharmacokinetics.

  2008cited by this paper
• Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization

  2008cited by this paper
• Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension

  2008cited by this paper
• The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.

  2007cited by this paper
• Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors

  2007cited by this paper
• Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

  2007cited by this paper
• Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.

  2006cited by this paper
• Safety issues associated with the use of angiotensin-converting enzyme inhibitors

  2006cited by this paper
• A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay

  2006cited by this paper
• Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation.

  2006cited by this paper
• Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

  2006cited by this paper
• Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild‐type angiotensin‐converting enzyme

  2006cited by this paper
• Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives

  2006cited by this paper
• The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots

  2005cited by this paper
• Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice*

  2004influential reference
• An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.

  2004cited by this paper
• Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming

  2004influential reference
• Ace revisited: A new target for structure-based drug design

  2003cited by this paper
• Roles of the Two Active Sites of Somatic Angiotensin‐Converting Enzyme in the Cleavage of Angiotensin I and Bradykinin Insights From Selective Inhibitors

  2003cited by this paper
• Nonlinear models for repeated measurement data: An overview and update

  2003cited by this paper
• Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme.

  2003influential reference
• Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors.

  2002cited by this paper
• Angiotensin II and trials of cardiovascular outcomes.

  2002cited by this paper
• Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors

  2002cited by this paper
• Ways to Fit a PK Model with Some Data Below the Quantification Limit

  2001influential reference
• Lipophilicity in PK design: methyl, ethyl, futile

  2001cited by this paper
• Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme.

  2000cited by this paper
• VolSurf: a new tool for the pharmacokinetic optimization of lead compounds.

  2000cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999influential reference
• RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.

  1999cited by this paper
• Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P.

  1998cited by this paper
• Plasma bradykinin in angio-oedema.

  1998cited by this paper
• Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning.

  1988cited by this paper
• Estimating population kinetics.

  1982cited by this paper

• Anti-hypertensive Function of Plant-derived Bioactive Peptides: A Review.

  2025cites this paper
• Identification of a Synthetic Peptide with Potential Angiotensin I-Converting Enzyme (ACE-1) Inhibitory Activity

  2025influential citation
• The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy

  2024cites this paper
• Proteomic Analysis of Human Macrophages Overexpressing Angiotensin-Converting Enzyme

  2024cites this paper
• Study on the domain selective inhibition of angiotensin-converting enzyme (ACE) by food-derived tyrosine-containing dipeptides.

  2021cites this paper
• Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin)

  2021cites this paper
• Structural changes in pH-responsive gelatin/hydroxypropyl methylcellulose phthalate blends aimed at drug-release systems.

  2021cites this paper
• Association of Angiotensin-Converting Enzyme gene polymorphism and Alzheimer's risk in Kashmiri population

  2021cites this paper
• Construction and Application of Membrane-bound Angiotensin-I Converting Enzyme System: A New Approach for the Evaluation of Angiotensin-I Converting Enzyme Inhibitory Peptides.

  2020cites this paper
• Interacting cogs in the machinery of the renin angiotensin system

  2019cites this paper
• The Coming of Age of the Angiotensin Hypothesis in Alzheimer’s Disease: Progress Toward Disease Prevention and Treatment?

  2018cites this paper
• Kehoe, P. G. (2018). The coming of age of the angiotensin hypothesis in Alzheimer's disease: Progress toward disease prevention and treatment?

  2018cites this paper
• DESIGN AND PHYSICOCHEMICAL CHARACTERIZATION OF LISINOPRIL–LOADED NANOCAPSULES FOR PAEDIATRIC USE

  2017cites this paper
• Alu insertion/deletion of ACE gene polymorphism might not affect significantly the serum bradykinin level in hypertensive patients taking ACE inhibitors

  2017cites this paper
• Preparation, Characterization and Electrochemical Application of ZnS/ZnAl2S4 Nanocomposite for Voltammetric Determination of Methionine and Tryptophan Using Modified Carbon Paste Electrode

  2016cites this paper
• Changes of Composition and Angiotensin I-Converting Enzyme-Inhibitory Activity During Douchi Fermentation

  2016cites this paper
• Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats

  2015cites this paper